On innovative drug shares: favorable new listing policies main catalysts

Pharm stocks have gained great market attention recently, buoyed by a rise in both valuations and public funds’ holdings. With favorable tailwind policies for biotech IPOs in mainland China and HK, innovative drug stocks are expected to embrace an even stronger rally in 2Q18